Cellbiotech Introduces Novel Anti-Hyperlipidemic Agent

Published: 2005-02-04 06:56:00

Updated: 2005-02-04 06:56:00

Cellbiotech Co., a domestic biotechnology venture company, announced this week that it has successfully completed a pre-clinical animal study for a novel anti-hyperlipidemic agent known as PROLAC-T.

Jointly performed with the Konkuk University, results from the animal study showed that PROLAC-...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK